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Abstract
Introduction:  Mutations  in  the  otoferlin  gene  are  responsible  for  auditory  neuropathy.
Objective:  To  investigate  the  prevalence  of  mutations  in  the  mutations  in  the  otoferlin  gene  in
patients with  and  without  auditory  neuropathy.
Methods:  This  original  cross-sectional  case  study  evaluated  16  index  cases  with  auditory  neu-
ropathy,  13  patients  with  sensorineural  hearing  loss,  and  20  normal-hearing  subjects.  DNA  was
extracted from  peripheral  blood  leukocytes,  and  the  mutations  in  the  otoferlin  gene  sites  were
ampliﬁed  by  polymerase  chain  reaction/restriction  fragment  length  polymorphism.
Results:  The  16  index  cases  included  nine  (56%)  females  and  seven  (44%)  males.  The  13  deaf
patients comprised  seven  (54%)  males  and  six  (46%)  females.  Among  the  20  normal-hearing  sub-
jects, 13  (65%)  were  males  and  seven  were  (35%)  females.  Thirteen  (81%)  index  cases  had
wild-type  genotype  (AA)  and  three  (19%)  had  the  heterozygous  AG  genotype  for  IVS8-2A-G
(intron 8)  mutation.  The  5473C-G  (exon  44)  mutation  was  found  in  a  heterozygous  state  (CG)
in seven  (44%)  index  cases  and  nine  (56%)  had  the  wild-type  allele  (CC).  Of  these  mutants,
two (25%)  were  compound  heterozygotes  for  the  mutations  found  in  intron  8  and  exon  44.  All
patients with  sensorineural  hearing  loss  and  normal-hearing  individuals  did  not  have  mutations
(100%).
Conclusion:  There  are  differences  at  the  molecular  level  in  patients  with  and  without  auditory
neuropathy.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved. Please cite this article as: da Silva MA, Piatto VB, Maniglia JV. Molecular approach of auditory neuropathy. Braz J Otorhinolaryngol.
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Abordagem  molecular  da  neuropatia  auditiva
Resumo
Introduc¸ão:  Mutac¸ões  no  gene  da  otoferlina  (OTOF)  são  responsáveis  pela  neuropatia  auditiva.
Objetivo: Investigar  a  prevalência  de  mutac¸ões  no  gene  OTOF  em  pacientes  com  e  sem  neu-
ropatia auditiva.
Método:  Estudo  de  casos  em  corte  transversal  sendo  avaliados  16  casos  índice  com  neuropatia
auditiva,  13  pacientes  com  deﬁciência  auditiva  sensorioneural  (DASN)  e  20  indivíduos  ouvintes.
DNA foi  extraído  de  leucócitos  do  sangue  periférico  e  regiões  do  gene  OTOF  foram  analisadas
pela técnica  PCR-RFLP.
Resultados:  Dos  16  casos  índice,  9  (56%)  são  do  gênero  feminino  e  7  (44%)  do  masculino.  Dos
13 pacientes  com  DASN,  7  (54%)  são  masculinos  e  6  (46%)  femininos.  Dos  20  ouvintes,  13  (65%)
são masculinos  e  7  (35%)  femininos.  Treze  (81%)  casos  índice  apresentam  o  genótipo  selvagem
(AA) e  3  (19%)  o  genótipo  heterozigoto  AG  para  a  mutac¸ão  IVS8-2A-G  (intron  8).  A  mutac¸ão
5473C-G  (exon  44)  foi  encontrada  em  heterozigose  (CG)  em  7  (44%)  dos  casos  índice  e  9  (56%)
apresentam  o  genótipo  selvagem  (CC).  Destes  mutantes,  dois  (25%)  são  heterozigotos  compostos
para as  mutac¸ões  encontradas  no  intron  8  e  exon  44.  Os  pacientes  com  DASN  e  os  ouvintes  não
apresentam  mutac¸ões  (100%).
Conclusão:  Existem  diferenc¸as,  ao  nível  molecular,  em  pacientes  com  e  sem  neuropatia  audi-
tiva.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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fter  the  mutations  in  GJB2  and  GJB6  gene,  which  account
or  approximately  80%  of  autosomal-recessive  nonsyndromic
earing  impairment  (ARNSHI),  mutations  in  the  otoferlin
ene  (OTOF)  are  the  most  frequent  genetic  cause  of  deafness
n  children.  This  type  of  hearing  loss  (HL)  is  more  compli-
ated,  considering  that  at  an  early  stage  it  may  present  as
uditory  neuropathy  (AN)  that  is  not  detected  by  neonatal
creening  based  on  otoacoustic  emission  testing.1
Auditory  neuropathy  is  a  unique  type  of  HL  in  which  tym-
anograms  are  normal,  the  acoustic  reﬂex  and  the  brainstem
uditory  evoked  potentials  (BAEP)  are  absent  or  severely
ltered,  and  the  outer  hair  cell  function  is  normal,  as  shown
y  the  presence  of  otoacoustic  emissions  (OAEs).  Patients
ith  this  disorder  can  show  varied  degrees  of  HL,  in  addi-
ion  to  severe  speech  comprehension  impairment,  which  is
isproportional  to  the  degree  of  hearing  loss.1
In  2003,  the  term  ‘‘autosomal-recessive  nonsyndromic
uditory  neuropathy’’  was  deﬁned,  due  not  only  to  the
udiological  characteristics,  but  also  to  genetic  discover-
es  related  to  mutations  in  the  OTOF  gene,  which  were
ssociated  with  this  type  of  hearing  loss.2 The  OTOF  gene,
ocated  on  chromosome  2  (2p23-p22),  contains  48  exons
nd  encodes  the  protein  otoferlin,  which  is  expressed  in
ochlear  inner  hair  cells  and  type  I  vestibular  hair  cells.3
ince  then,  molecular  studies  have  been  published  that
llowed  the  identiﬁcation  of  mutations  in  the  OTOF  gene  and
ssociated  them  to  the  autosomal-recessive  nonsyndromic
2--12N.
Therefore,  this  study  aimed  to  investigate  the  prevalence
f  mutations  in  the  OTOF  gene:  2416T-A  (Y730X)  in  exon  18,3
VS8-2-A-G  in  intron  8/exon  9,6 2485C-T  (Q829X)  in  exon  22,5
t
e
t473C-G  (Pro1825Ala)  in  exon  44,5 and  3032T-C  (Leu1011Pro)
n  exon  26,9 in  patients  with  AN  and  in  patients  with  non-
yndromic  HL.
ethods
his  cross-sectional  study  was  carried  out  from  April  1,
010  until  July  30,  2011;  of  1230  cases  of  nonsyndromic
ensorineural  hearing  loss  (NSHL)  treated  at  the  Hearing
oss  Outpatient  Clinic  of  the  institution,  16  patients  were
elected  (NPT  group--neuropathy),  of  both  genders,  with  AN.
hese  were  deemed  index  cases,  according  to  the  follow-
ng  inclusion  criteria:  normal  otoscopy,  diagnosis  of  NSHL
y  pure  tone  audiometry,  presence  of  otoacoustic  emis-
ions  and/or  cochlear  microphonic  in  BAEP;  absence  of  BAEP
aves  or  severe  alteration  in  their  morphology;  normal  MRI;
bsence  of  risk  factors  (maternal--fetal  infections,  menin-
itis,  ototoxic  drugs)  or  peripheral  neuropathies.  Exclusion
riteria  included  a  diagnosis  of  conductive  or  mixed  hearing
oss,  the  presence  of  risk  factors  or  peripheral  neuropathies,
nd  an  age  >65  years.
A  total  of  13  patients  of  both  genders  (NSHL  group)  were
lso  selected,  who  had  received  a  diagnosis  of  NSHL  and
hose  audiological  tests  did  not  match  the  clinical  picture
f  AN  and  had  no  mutations  in  the  connexin  26  and  GJB6
enes.
For  the  Control  group  (CG  group),  20  individuals  of  both
enders  were  selected,  with  no  hearing  complaints,  with
ormal  otoscopy  and  who  were  unrelated  to  the  patients  in
he  NPT  and  NSHL  groups.The  index  cases,  patients,  and  controls  were  of  the  same
thnicity,  age  ≤65  years,  with  no  consanguinity,  and  from
he  same  geographical  area.
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The  study  was  approved  by  the  Ethics  Committee  of  the
institution  (Edict  No.  44/2010).  Genomic  DNA  was  extracted
from  peripheral  blood  samples  using  the  GE  Illustra  extrac-
tion  kit  -- Blood  Genomicprep  Mini  Spin  KitTM (GE  Healthcare
UK  Ltd)  according  to  the  manufacturer’s  protocol.
All  ﬁve  mutations  analyzed  in  the  OTOF  gene  are  identi-
ﬁed  by  their  positions  in  the  NCBI  Gene  Bank  RefSeqGene:
NG  009937.1.  Polymerase  chain  reaction/restriction  frag-
ment  length  polymorphism  (PCR/RFLP)  tests  were  used  for
the  molecular  analysis.
Each  of  the  ﬁve  PCR  reactions  was  processed  in  a  tem-
perature  cycler  (Bioer  Technology®,  Model  TC-XPG)  using
25  uL  ﬁnal  reaction  volume,  containing  the  following:  1  --
DNA  (200--300  ng);  2  --  10  pmol  of  each  primer  (forward  and
reverse);  3  --  Reagent  Kit  FideliTaqTM PCR  MasterMix  (2×)
(GE  HEALTHCARE®)  using  protocol  according  to  the  manu-
facturer’s  instructions.
The  following  standard  cycle  for  the  PCR  reactions  was
used,  differing  only  in  the  primer  annealing  time,  which  is
speciﬁc  for  each  pair  used:  initial  denaturation  at  94◦ C  for
3  min,  35  repeated  cycles  of  60  s  at  94◦ C  for  denaturation,
60  s  at  X ◦C  for  primer  annealing  (for  the  2416T-A  mutation:
56 ◦C;  IVS8-2A-G:  51 ◦C;  2485C-T:  58 ◦C;  5473C-G  mutation:
59 ◦C;  3032T-C  mutation:  52 ◦C),  and  extension  of  2  minutes
at  72 ◦C  and  10  min  at  72 ◦C  for  the  ﬁnal  extension.  The  frag-
ments  ampliﬁed  by  PCR  were  respectively  submitted  to  RFLP
analysis,  using  5  U  of  the  following  enzymes:  DdeI  enzyme,
BGlII,  BfaI,  FauI  and  MspI  (New  England  Biolabs®).
The  products  of  the  reactions  (PCR/RFLP)  were  added
to  bromophenol  blue  and  submitted  to  electrophoresis  on
2%  agarose  gel  in  Tris--borate--EDTA  1×  buffer  containing
ethidium  bromide  (0.5  ug/mL),  after  which  the  gels  were
illuminated  with  UV  lighting  and  photographed.
Statistical  analysis
The  results  were  previously  submitted  to  descriptive  statis-
tics  to  determine  normality.  The  Chi-squared  test  was  used
to  compare  independent  variables  with  normal  distribution
and  the  Kruskal--Wallis  test  for  samples  with  non-normal
distribution,  in  addition  to  odds  ratio  with  a  conﬁdence
interval  of  95%  (95%  CI).  The  level  of  signiﬁcance  was  set  at
5%.  Statistical  tests  were  performed  using  GraphPad  InStat
software  release  3.0  (GraphPad  Software  Inc  --  San  Diego,
CA,  United  States).  Consistency  of  genotype  distribution
with  the  Hardy-Weinberg  equilibrium  was  assessed  by  exact
tests.13
Results
Of  a  total  of  16  index  cases  from  the  NPT  group,  nine  (56%)
were  females  and  seven  (44%)  were  males.  Age  ranged  from
8  to  65  years  for  females  (mean  M  24.2  years,  SD  ±  20.1)  and
for  males  between  1  and  38  years  (M  14.1  years,  SD  ±  15.7),
with  no  statistically  signiﬁcant  difference  (p  =  0.29).
Of  the  13  patients  in  the  NSHL  group,  seven  (54%)  were
males  and  six  (46%)  were  females.  Age  varied  from  7  to  37
years  for  males  (M  22.7  years,  SD  ±  12.6)  and  between  12
and  45  years  for  females  (M  33.3  years,  SD  ±  12.3),  with  no
signiﬁcant  difference  (p  =  0.15).
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Regarding  the  20  individuals  in  the  CG,  13  (65%)  were
ales  and  seven  (35%)  were  females.  Age  ranged  from  19
o  44  years  for  males  (M  28.5  years,  SD  ±  7.2)  and  between
0--35  years  for  females  (M  26.3  years,  SD  ±  6.3),  with  no
igniﬁcant  difference  (p  =  0.49).
Considering  the  demographic  variables  among  patients
n  the  three  groups,  there  was  a  prevalence  of  females  in
ll  three,  although  it  was  not  signiﬁcant  (p  =  0.49).  Both  the
SHL  and  CG  groups  had  a  higher  prevalence  in  the  young
dult  age  range,  totaling  55%  and  95%,  respectively.  The  NPT
roup  had  higher  prevalence  in  the  infant  group  (38%).  The
tatistical  analysis  for  this  demographic  variable  was  not  sig-
iﬁcant  between  groups  (p  =  0.37).  Similarly,  the  mean  ages
mong  the  three  groups  showed  no  signiﬁcant  differences
p  =  0.091;  Table  1).
Table  2  shows  the  distribution,  in  percentages,  of  the
enotypes  found  in  the  three  groups  assessed  for  the  ﬁve
utations  in  the  OTOF  gene.  In  the  NPT  group,  13  (81%)  index
ases  had  the  wild  genotype  (AA)  and  three  (19%)  had  the
eterozygous  genotype  AG  for  IVS8-2A-G  mutation  (intron
).  The  5473C-G  mutation  (exon  44)  was  found  in  heterozy-
ous  form  (CG)  in  seven  (44%)  of  the  index  cases  and  nine
56%)  had  the  wild  allele  (CC).  In  the  NSHL  and  CG  groups,
00%  of  patients  had  none  of  the  analyzed  mutations  in  the
TOF  gene.
Thus,  in  the  NPT  group,  there  were  eight  (50%)  index
ases  with  mutations  in  the  OTOF  gene,  one  (12.5%;  F1.3)
eterozygous  for  the  mutation  IVS8-2A-G,  ﬁve  (62.5%;  F1.2,
4.1,  FBT1,  FBT3.2,  and  FBT4.2)  compound  heterozygous
or  the  mutation  5473C-G,  and  two  (25%;  F1.1  and  F5GI)
ompound  heterozygous  for  the  mutations  found  respec-
ively  in  intron  8  and  exon  44.  Of  the  normal-hearing  family
embers,  the  mother  of  Family  1  (F1.M) is  a  compound  het-
rozygous  for  the  mutations  analyzed  in  intron  8  and  exon  44
nd  the  mothers  of  Families  FBT3  and  FBT4  are  heterozygous
nly  for  the  5473C-G  mutation  (Table  3).
The  NPT  group  was  assessed  for  the  Hardy--Weinberg
quilibrium  in  relation  to  mutations  found  in  intron  8  and
xon  44.  According  to  the  calculations  made,  allelic  fre-
uencies  A  (wild-type  allele)  and  G  (mutant  allele)  of  the
VS8-2A-G  mutation,  for  the  index  cases  of  the  NPT  group,
ere  A  =  0.91  and  G  =  0.09.  The  observed  genotypic  fre-
uencies  of  the  wild  homozygous  form  (AA-13),  mutant
eterozygous  (AG-3),  and  mutant  homozygous  (GG-0)  of
hese  index  cases  are  consistent  with  the  expected  fre-
uencies  for  the  Hardy-Weinberg  equilibrium  (2 =  0.171;
 =  0.68).  Regarding  the  5473C-G  mutation,  the  allelic  fre-
uencies  C  (wild-type  allele)  and  G  (mutant  allele)  for  the
ndex  cases  of  the  NPT  group  were  C  =  0.78  and  G  =  0.22.  For
his  mutation,  the  genotypic  frequencies  observed  in  the
ild  homozygous  form  (CC-9),  mutant  heterozygous  (GC-7),
nd  mutant  homozygous  (GG-0)  of  these  index  cases  are
lso  in  agreement  with  the  expected  frequencies  for  the
ardy--Weinberg  equilibrium  (2 =  0.125;  p  =  0.26).
Regarding  the  degree  of  hearing  loss  found  in  the  index
ases  of  the  NPT  group,  three  (19%)  had  mild,  ﬁve  (31%)  mod-
rate,  ﬁve  (31%)  severe,  and  three  (19%)  profound  hearing
oss.  In  the  NSHL  group,  four  (31%)  had  moderate,  two  (15%)
evere,  and  seven  (54%)  profound  hearing  loss.  There  were
o  mild  cases  in  this  group.  Statistical  analysis  for  the  vari-
ble  degree  of  hearing  loss  showed  no  signiﬁcant  difference
etween  groups  (p  =  0.124).
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Table  1  Distribution  of  demographic  variables  of  index  cases  in  the  NPT  group,  patients  from  the  NSHL  group,  and  individuals
from the  Control  group.
Variables  NPT  group  (n  =  16)  NSHL  group  (n  =  13)  Control  group  (n  =  20)  p
Gender  n  (%)  n  (%)  n  (%)
Male 7  (44)  6  (46)  7  (35)  0.49a
Female  9  (56)  7  (54)  13  (65)
Age classiﬁcation  n  (%)  n  (%)  n  (%) 0.37a
Infant  1  (06)  0  (00)  0  (00)
Child 6  (38)  2  (15)  0  (00)
Adolescent  3  (19) 2  (15) 0  (00)
Young adult 4  (25) 7  (55) 19  (95)
Adult 2  (12) 2  (15) 1  (05)
Elderly 0  (00)  0  (00)  0  (00)
Age M  ±  SD M  ±  SD  M  ±  SD  p
Years  19.8  ±  18.5  27.6  ±  13.1  19.  ±  18.5  0.091b
M ± SD, mean ± standard deviation.
4
i
c
s
w
s
p
H
D
A
o
pa Chi-squared test.
b Kruskal--Wallis test.
Due  to  mutation  identiﬁcation  only  in  intron  8  and  exon
4  in  the  OTOF  gene,  Table  4  shows  the  degree  of  hearing  loss
n  the  NPT  group  index  cases  and  genotypes  found  in  these
ases,  through  the  molecular  analysis  of  these  regions.
Among  the  index  cases  with  mutation,  those  with  the
evere  (four;  25%)  and  profound  (three;  19%)  hearing  loss
ere  more  prevalent  than  those  without  mutation  (only  one
evere  HL,  6%)  of  the  same  group,  which  showed  a  higher
revalence  of  mild  (three;  19%)  and  moderate  (four;  25%)
L,  with  a  signiﬁcant  difference  (p  =  0.022).
b
d
A
l
Table  2  Distribution,  in  percentages,  of  the  genotypes  found  in  
gene.
Genotype  NPT  group  (n  =  16)  n  (%)  NSHL
2416T-A  Exon  18
TT  16  (100)  13  (1
TA 0  0  
AA 0  0  
IVS8-2A-G Intron  8
AA 13  (81)  13  (1
AG 3  (19)  0  
GG 0  0  
2485C-T Exon  22
CC  16  (100)  13  (1
CT 0  0  
TT 0  0  
5473C-G Exon  44
CC  9  (56)  13  (1
CG 7  (44)  0  
GG 0  0  
3032T-C Exon  26
TT 16  (100)  13  (1
TC 0  0  
CC 0  0  iscussion
N  is  a  hearing  disorder  characterized  by  severe  distortion
r  absence  of  BAEP  with  preserved  OAEs,  thus  indicating  the
resence  of  outer  hair  cell  integrity.14
Among  the  previously  identiﬁed  causes  of  AN  are  hyper-
ilirubinemia,  neonatal  hypoxia,  or  neurodegenerative
iseases.  However,  there  have  been  reports  of  ‘‘isolated’’
N,  i.e.,  without  any  risk  factors,  and  no  physiopatho-
ogical  mechanism  has  been  proposed  to  explain  these
the  three  groups  assessed  for  the  ﬁve  mutations  in  the  OTOF
 group  (n  =  13)  n  (%)  Control  group  (n  =  20)  n  (%)
00)  20  (100)
0
0
00)  20  (100)
0
0
00)  20  (100)
0
0
00)  20  (100)
0
0
00)  20  (100)
0
0
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Table  3  Genotypes  found  in  the  NPT  group  index  cases  among  the  ﬁve  mutations  assessed  in  the  OTOF  gene.
Index  cases  (NPT  Group)
and  normal-hearing
family  members
2416T-A
exon  18
IVS8-2A-G
intron  8
2485C-T
exon  22
5473C-G
exon  44
3032T-C
exon  26
F1.P  −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F1.M −/−  (TT)  −/+  (AG)  −/−  (CC)  −/+  (CG)  −/−  (TT)
F1.1 −/−  (TT)  −/+  (AG)  −/−  (CC)  −/+  (CG)  −/−  (TT)
F1.2 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
F1.3 −/−  (TT)  −/+  (AG)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F2.2 M  −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F2.3 −/−  (TT) −/−  (AA) −/−  (CC) −/−  (CC)  −/−  (TT)
F2.6 −/−  (TT) −/−  (AA) −/−  (CC) −/−  (CC) −/−  (TT)
F2.11 −/−  (TT) −/−  (AA) −/−  (CC) −/−  (CC) −/−  (TT)
F3.P −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F3.M −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F3.2 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F3.3 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F4.1 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
F5.GI −/−  (TT)  −/+  (AG)  −/−  (CC)  −/+  (CG)  −/−  (TT)
F5.GII −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
F6.1 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
FBT1 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
FBT2 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
FBT3.M −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
FBT3.1 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
FBT4.M −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
FBT4.1 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
FBT4.2 −/−  (TT)  −/−  (AA)  −/−  (CC)  −/+  (CG)  −/−  (TT)
FBT5.GI −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
FBT5.GII −/−  (TT)  −/−  (AA)  −/−  (CC)  −/−  (CC)  −/−  (TT)
Underlined, index cases with auditory neuropathy (NPT). F, family; P, father of the index case; M, mother of the index case; GI, twin; I
GII, twin II; −/−, wild homozygous genotype for the analyzed mutation; −/+, heterozygous genotype for the analyzed mutation; −/+,
heterozygous genotype for the mutation analyzed in normal-hearing family member.
Table  4  Degree  of  hearing  loss  and  the  genotypes  found  in  Intron  8  and  Exon  44  of  the  OTOF  gene,  in  index  cases  of  NPT  group.
Group  NPT  Degree  of  hearing  loss  IVS8-2A-G  intron  8  5473C-G  exon  44
F1.1  Profound  −/+  (AG)  −/+  (CG)
F1.2 Severe  −/−  (AA)  −/+  (CG)
F1.3 Severe  −/+  (AG)  −/−  (CC)
F2.2 M  Mild  −/−  (AA)  −/−  (CC)
F2.3 Moderate  −/−  (AA)  −/−  (CC)
F2.6 Mild  −/−  (AA)  −/−  (CC)
F2.11 Moderate  −/−  (AA)  −/−  (CC)
F3.3 Moderate  −/−  (AA)  −/−  (CC)
F4.1 Severe  −/−  (AA)  −/+  (CG)
F5.GI Profound  −/+  (AG)  −/+  (CG)
F6.1 Severe  −/−  (AA)  −/−  (CC)
FBT1 Moderate  −/−  (AA)  −/+  (CG)
FBT2 Moderate  −/−  (AA)  −/−  (CC)
FBT3.1 Severe  −/−  (AA)  −/+  (CG)
FBT4.2 Profound  −/−  (AA)  −/+  (CG)
FBT5.GII Mild  −/−  (AA)  −/−  (CC)
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ases.  Recent  advances  in  genetic  research  has  allowed
 new  approach  to  elucidate  the  physiopathology  of  this
isease.15,16
Given  the  above,  this  study  aimed  to  investigate  the
revalence  of  ﬁve  mutations  in  the  OTOF  gene  in  patients
ith  AN  diagnosis,  in  normal-hearing  subjects  and  in  patients
ith  NSHL.  These  were  included  in  order  to  determine
hether  mutations  in  the  OTOF  gene  could  be  identiﬁed  in
ormal-hearing  subjects  and  in  patients  with  NSHL  without
utations  in  other  genes  and  without  AN.
Regarding  the  demographic  variables,  there  was  a  preva-
ence  of  females  in  the  three  study  groups,  although  it  was
ot  statistically  signiﬁcant.  The  NSHL  and  CG  groups  had  a
igher  prevalence  in  the  young  adult  age  range  and  the  NPT
roup  had  a  higher  prevalence  in  the  infant  age  range,  but
ithout  a  signiﬁcant  difference.  These  data  are  consistent
ith  the  few  published  reports  on  the  prevalence  of  gender
nd  age  range  related  to  the  OTOF  gene.17,18
Most  reports  of  mutations  identiﬁed  in  the  OTOF  gene
ave  been  described  in  homozygous  form  and  in  con-
anguineous  families.3,4,6,9,18--22 Among  the  ﬁve  mutations
nalyzed  in  the  OTOF  gene,  only  the  IVS8-2A-G  mutation
n  intron  8  and  5473C-G  mutation  in  exon  44  were  found,
ffecting  50%  of  the  study  index  cases.  In  contrast  to
he  literature,  all  index  cases  were  the  offspring  of  non-
onsanguineous  marriages,  demonstrating  that  mutations  in
he  OTOF  gene  that  are  associated  with  AN  may  occur  in
hese  cases.
Heterozygous  cases  in  patients  with  AN  have  been
escribed,  with  or  without  consanguinity.2,5,8,10--12,23,24 In  the
resent  study,  the  IVS8-2A-G  mutation  was  found  in  het-
rozygous  state  (one  mutant  allele)  in  12.5%  of  index  cases,
ith  the  same  occurring  with  the  5473C-G  mutation,  which
as  found  in  62.5%  of  cases.  In  25%  of  cases,  the  two  muta-
ions  identiﬁed  occurred  at  the  same  time  in  the  same
ndividual,  which,  therefore,  are  called  compound  heterozy-
otes.  These  two  mutations,  as  well  as  the  other  three
nalyzed,  were  not  found  in  the  NSHL  group  (100%)  nor
n  the  CG  group.  These  data  are  in  agreement  with  the
iterature.2,5,8,10--12,23,24
In  2000,  the  IVS8-2A-G  mutation  was  ﬁrst  described  in
ts  homozygous  state  in  three  brothers  from  India  born  to
onsanguineous  parents  and  in  its  heterozygous  state  in
he  parents  and  unaffected  siblings,  and  was  not  identiﬁed
n  109  normal-hearing  individuals  from  the  control  group.6
here  have  been  no  further  reports  on  this  mutation.  The
473C-G  mutation  was  described  in  compound  heterozygos-
ty  in  a  Spanish  family,  with  the  2485C-T  mutation  in  exon
2,  identiﬁed  in  another  allele.5
Similarly,  there  have  been  no  further  reports  of  the  afore-
entioned  mutation  in  exon  44.
The  IVS8-2A-G  mutation,  by  creating  a  premature  stop
odon,  and  the  5473C-G  mutation,  by  altering  the  binding
apacity  with  Ca+2 in  the  wild-type  gene,  are  considered
athogenic  when  in  their  homozygous  state.3,5 In  this  study,
oth  were  found  in  compound  heterozygous  states  only  in
ndex  cases  with  AN  (F1.1  and  F5.GI),  which  could  explain
he  molecular  cause  of  hearing  loss  in  these  individuals,  as
he  AN  phenotype  has  been  observed  in  patients  with  two
utations  affecting  all  isoforms  of  otoferlin  or  one  mutation
ffecting  the  long  isoform  and  another,  the  short  isoform.
his  means  that  any  combination  of  biallelic  mutations  in
i
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he  OTOF  gene  may  result  in  AN,  as  they  are  partially  related
o  the  nature  (truncated  or  non-truncated)  or  the  location
long  or  short  isoform)  of  these  mutations.23
However,  the  same  mutations  were  also  found  in
ompound  heterozygosis  in  the  normal-hearing  mother
F1.M)  of  the  compound  heterozygous  index  case  (F1.1).  As
he  mother  has  normal  hearing,  the  cause  of  HL  in  the  index
ase  may  be  due  to  other  existing  mutations  in  other  exons
r  other  splice  sites,  or  more  complex  mutations,  such  as
arge  deletions  or  other  sequence  rearrangements,  which
equire  a  more  speciﬁc  molecular  approach  than  used  here.
imilarly,  these  hypotheses  may  also  be  applied  to  explain
he  other  six  HL  index  cases,  as  they  are  carriers  of  one  of
he  mutations  identiﬁed  in  only  one  of  the  alleles.
Brazilian  references  have  not  reported  the  mutations
dentiﬁed  in  this  study,10--12 and  only  one  of  them  identi-
ed  the  2485C-T  mutation  in  exon  22  with  heterozygosity  in
.5%  of  cases  of  patients  with  non-syndromic  sensorineural
L  (1/200).10
Estimates  of  the  prevalence  of  AN  in  deaf  individuals
ange  from  1%  to  19%. 25--28 In  Brazil,  the  prevalence  of  AN
mong  all  cases  of  deafness  is  1.2%.29 This  range  of  varia-
ion  may  be  due  to  the  fact  that  different  populations  were
tudied  or  due  to  differences  in  the  criteria  used  to  iden-
ify  patients  with  this  disease.  The  prevalence  of  AN  in  a
opulation  without  risk  factors  is  not  well  established.9 In
he  present  study,  all  the  criteria  for  inclusion  and  exclusion
ere  strictly  followed,  thus  determining  the  prevalence  of
.3%  of  cases  with  AN  in  a  population  with  sensorineural
earing  loss  during  the  study  period.
Moreover,  the  Brazilian  estimate  of  the  magnitude  of  HL
n  patients  with  AN  is  29.6%  mild,  55.5%  moderate,  7.4%
evere,  and  7.5%  profound  HL.29 In  the  present  study  19%
ad  mild,  31%  moderate,  31%  severe,  and  19%  profound  HL.
mong  the  index  cases  with  mutations  in  the  OTOF  gene,
e  found  a  statistically  signiﬁcant  prevalence  of  severe  and
rofound  HL  compared  to  the  mild  and  moderate  HL  in
ndex  cases  without  mutation.  The  intensity  of  hearing  loss
aused  by  AN  can  range  from  mild  to  profound,  with  a  dis-
roportionate  decrease  in  understanding  speech  that  does
ot  correspond  to  the  pure-tone  audiogram.
There  is  some  homogeneity  in  the  description  of  the  phe-
otype  of  patients  with  mutations  in  the  OTOF  gene,  that
s  characterized  by  a congenital  or  pre-lingual  profound  HL
ot  associated  with  other  abnormalities,  as  the  index  cases
tudied.  Therefore,  AN  is  the  only  phenotypic  expression  of
utations  in  the  OTOF  gene,  with  hearing  loss  identiﬁed  by
he  relative  preservation  of  outer  hair  cell  function.9,30
The  presence  of  OAEs  in  the  ﬁrst  months  of  life  has  impor-
ant  implications  for  neonatal  screening  programs,  such  as
nitial  screening.  In  the  case  of  AN,  there  is  a  risk  that  this
oss  will  go  undiagnosed,  for  although  these  patients  have
evere  to  profound  degree  of  hearing  loss,  they  would  be
ncluded  among  the  cases  classiﬁed  as  ‘‘no  alteration  or  nor-
al’’  because  OAEs  reﬂect  the  auditory  function  in  outer
air  cells  and  their  presence  does  not  exclude  alterations  of
nner  hair  cells,  in  synapses,  or  in  the  auditory  nerve.28
In  the  context  of  HL  investigation,  it  is  important  to  take
nto  account  the  type  of  AN  loss,  which  is  often  misdiag-
osed.  Therefore,  when  assessing  a  child  or  patient  with
eafness  in  the  presence  of  OAEs,  the  hypothesis  of  AN
as  to  be  raised  and  genetic  testing  for  mutations  in  the
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OTOF  gene  research  should  be  performed,  as  they  were  per-
formed  in  this  study,  allowing  an  accurate  etiologic  diagnosis
to  provide  appropriate  audiological  treatment  in  a  timely
manner.28
Potential  limitations  regarding  the  study  ﬁndings  deserve
consideration;  despite  the  positive  results,  they  should  be
interpreted  with  caution  and  should  be  corroborated  by
independent,  multicenter  studies  to  determine  the  true
prevalence  of  mutations  in  the  OTOF  gene  and  the  associa-
tion  with  AN  in  the  Brazilian  population.
Conclusion
The  evidence  of  association  between  mutations  in  the  OTOF
gene  and  AN  indicates  that  there  are  differences  at  the
molecular  level  in  patients  with  and  without  this  type  of
hearing  loss;  in  the  absence  of  risk  factors,  the  combination
of  severe  distortion  or  absence  of  BAEP  in  the  presence  of
OAEs  should  direct  the  diagnosis  of  AN  and  the  screening  for
mutations  in  the  OTOF  gene.  Molecular  tests  are  valuable
diagnostic  complements,  not  only  individually,  but  also  as  a
screening  method  for  a  neonatal  or  population  study.
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